Katrina Thornber, Author at European Medical Journal - Page 12 of 50

Saliva Testing Identifies Early Risk for Cancer and Chronic Diseases

Saliva-based DNA markers could predict cancer, heart disease, and more—offering a non-invasive future for early diagnosis.

MVA-BN Vaccine Offers Safe Mpox Protection in At-Risk Groups

A German multicentre study shows MVA-BN vaccination is safe and moderately effective in preventing mpox, especially in HIV-negative individuals.

Dupilumab Linked to Increased Psoriasis Risk in Atopic Dermatitis

Given dupilumab’s well-documented benefits in controlling moderate to severe AD, clinicians are advised to weigh this potential risk carefully against its therapeutic advantages.

AI Achieves High Accuracy in Automated Echocardiogram Interpretation

AI now matches experts in echocardiogram interpretation, promising faster, more accessible heart diagnostics for all patients.

EAN 2025: Blood Biomarker sNfL Predicts MS Relapses Up to a Year in Advance

Blood biomarker sNfL predicts MS relapses up to a year in advance, offering new hope for earlier intervention.

EAN 2025: ChatGPT-4o Rivals Neurology Experts in Diagnosing and Managing Polyneuropathy

AI tool GPT-4o boosts diagnosis accuracy for nerve disorders, helping non-specialists match expert recommendations in real cases.

EAN 2025: Nightmares Linked to Faster Ageing and Premature Mortality

Frequent nightmares accelerate ageing and triple risk of early death, highlighting a new target for preventive healthcare.

EAN 2025: Blood Test for Insulin Resistance Predicts Cognitive Decline in Alzheimer’s

A routine blood test for insulin resistance can predict which Alzheimer’s patients are at risk of rapid cognitive decline.

EAN 2025: Nocturnal Heart Rate Can Predict Stroke and Depression Years in Advance

Nighttime heart rate variability may reveal hidden risks for stroke, depression, and dementia, years before symptoms appear.

New Evidence Supports Finerenone Use in Heart Failure, Regardless of Frailty

Finerenone benefits heart failure patients with preserved ejection fraction, regardless of frailty, supporting its wider clinical use.